Scott M. Lippman

Dr. Scott M. Lippman


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
JKJacqueline Kerr
Jacqueline Kerr
CACheryl Anderson
Cheryl Anderson
SLScott M. Lippman
Scott M. Lippman

9 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDaniel Martin
Daniel Martin
MDMaria S. Degese
Maria S. Degese
LVLynn Vitale-Cross
Lynn Vitale-Cross
RIRamiro Iglesias-Bartolome
Ramiro Iglesias-Bartolome
JVJuan Luis Callejas Valera
Juan Luis Callejas Valera
JGJ.Silvio Gutkind
J.Silvio Gutkind
Dysregulation of the Hippo signaling pathway and the consequent YAP1 activation is a frequent event in human malignancies, yet the underlying molecular mechanisms are still poorly understood. A pancancer analysis of core Hippo kinases and their candidate regulating molecules revealed few alterations in the canonical Hippo pathway, but very frequent genetic alterations in the FAT family of atypical cadherins. By focusing on head and neck squamous cell carcinoma (HNSCC), which displays frequent FAT1 alterations (29.8%), we provide evidence that FAT1 functional loss results in YAP1 activation. Mechanistically, we found that FAT1 assembles a multimeric Hippo signaling complex (signalome), resulting in activation of core Hippo kinases by TAOKs and consequent YAP1 inactivation. We also show that unrestrained YAP1 acts as an oncogenic driver in HNSCC, and that targeting YAP1 may represent an attractive precision therapeutic option for cancers harboring genomic alterations in the FAT1 tumor suppressor genes.

17 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
Ruchi AgasheRuchi Agashe
Ruchi Agashe
SLScott M. Lippman
Scott M. Lippman
RKRazelle Kurzrock
Razelle Kurzrock
The JAK/STAT axis is implicated in cancer, inflammation, and immunity. Numerous cytokines/growth factors affect JAK/STAT signaling. JAKs (JAK1, JAK2, JAK3, and TYK2) noncovalently associate with cytokine receptors, mediate receptor tyrosine phosphorylation, and recruit ≥1 STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). Tyrosine-phosphorylated STATs dimerize and are then transported into the nucleus to function as transcription factors. Signaling is attenuated by specific suppressor of cytokine signaling proteins, creating a negative feedback loop. Both germline mutations and polymorphisms of JAK family members correlate with specific diseases: Systemic lupus erythematosus (TYK2 polymorphisms); severe combined immunodeficiency (JAK3 mutations); pediatric acute lymphoblastic leukemia (TYK2 mutations); and hereditary thrombocytosis (JAK2 mutations). Somatic gain-of-function JAK mutations mainly occur in hematologic malignancies, with the activating JAK2 V617F being a myeloproliferative disorder hallmark; it is also seen in clonal hematopoiesis of indeterminate potential. Several T-cell malignancies, as well as B-cell acute lymphoblastic leukemia, and acute megakaryoblastic leukemia also harbor JAK family somatic alterations. On the other hand, JAK2 copy-number loss is associated with immune checkpoint inhibitor resistance. JAK inhibitors (jakinibs) have been deployed in many conditions with JAK activation; they are approved in myeloproliferative disorders, rheumatoid and psoriatic arthritis, atopic dermatitis, ulcerative colitis, graft-versus-host disease, alopecia areata, ankylosing spondylitis, and in patients hospitalized for COVID-19. Clinical trials are investigating jakinibs in multiple other autoimmune/inflammatory conditions. Furthermore, dermatologic and neurologic improvements have been observed in children with Aicardi–Goutieres syndrome (a genetic interferonopathy) treated with JAK inhibitors.

17 March 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
JHJuan Pablo Hinestrosa
Juan Pablo Hinestrosa
RKRazelle Kurzrock
Razelle Kurzrock
JLJean M. Lewis
Jean M. Lewis
NSNicholas Schork
Nicholas Schork
GSGregor Schroeder
Gregor Schroeder
RKRajaram Krishnan
Rajaram Krishnan
Background: Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage, curable cancers uses biomarkers present in circulating extracellular vesicles (EVs). To explore the feasibility of this approach, we developed an EV-based blood biomarker classifier from EV protein profiles to detect stages I and II pancreatic, ovarian, and bladder cancer. Methods: Utilizing an alternating current electrokinetics (ACE) platform to purify EVs from plasma, we use multi-marker EV-protein measurements to develop a machine learning algorithm that can discriminate cancer cases from controls. The ACE isolation method requires small sample volumes, and the streamlined process permits integration into high-throughput workflows. Results: In this case-control pilot study, comparison of 139 pathologically confirmed stage I and II cancer cases representing pancreatic, ovarian, or bladder patients against 184 control subjects yields an area under the curve (AUC) of 0.95 (95% CI: 0.92 to 0.97), with sensitivity of 71.2% (95% CI: 63.2 to 78.1) at 99.5% (97.0 to 99.9) specificity. Sensitivity is similar at both early stages [stage I: 70.5% (60.2 to 79.0) and stage II: 72.5% (59.1 to 82.9)]. Detection of stage I cancer reaches 95.5% in pancreatic, 74.4% in ovarian (73.1% in Stage IA) and 43.8% in bladder cancer. Conclusions: This work demonstrates that an EV-based, multi-cancer test has potential clinical value for early cancer detection and warrants future expanded studies involving prospective cohorts with multi-year follow-up.

1 February 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
WWWilliam William
William William
VPVassiliki Papadimitrakopoulou
Vassiliki Papadimitrakopoulou
JLJ. Jack Lee
J. Jack Lee
LMLi Mao
Li Mao
ECEzra E. W. Cohen
Ezra E. W. Cohen
SLScott M. Lippman
Scott M. Lippman
Oral premalignant lesions (OPLs), often clinically recognized as leukoplakia or erythroplakia, are considered risk factors for development of oral cancer. Oral premalignant lesions are a clinical manifestation of what can be a diffuse process of field cancerization. In patients with treated head and neck cancers, field cancerization contributes to development of second primary tumors, a significant cause of morbidity and mortality.1 Systemic chemoprevention has been proposed as a method to address the entire mucosal field at risk to halt or reverse carcinogenesis.2 However, a standard head neck cancer chemoprevention approach has yet to be developed, despite extensive previous clinical investigations of various retinoids,3-7 interferon,8 celecoxib,9 ONYX-015,10 and Bowman Birk inhibitor concentrate,11 among other candidate preventive drugs.

1 January 2016 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
TKThomas W. Kensler
Thomas W. Kensler
ASAvrum Spira
Avrum Spira
JGJudy E. Garber
Judy E. Garber
ESEva Szabo
Eva Szabo
JLJ. Jack Lee
J. Jack Lee
SLScott M. Lippman
Scott M. Lippman
We have entered a transformative period in cancer prevention (including early detection). Remarkable progress in precision medicine and immune-oncology, driven by extraordinary recent advances in genome-wide sequencing, big-data analytics, blood-based technologies, and deep understanding of the tumor immune microenvironment (TME), has provided unprecedented possibilities to study the biology of premalignancy. The pace of research and discovery in precision medicine and immunoprevention has been astonishing and includes the following clinical firsts reported in 2015: driver mutations detected in circulating cell-free DNA in patients with premalignant lesions (lung); clonal hematopoiesis shown to be a premalignant state; molecular selection in chemoprevention randomized controlled trial (RCT; oral); striking efficacy in RCT of combination chemoprevention targeting signaling pathway alterations mechanistically linked to germline mutation (duodenum); molecular markers for early detection validated for lung cancer and showing promise for pancreatic, liver, and ovarian cancer. Identification of HPV as the essential cause of a major global cancer burden, including HPV16 as the single driver of an epidemic of oropharyngeal cancer in men, provides unique opportunities for the dissemination and implementation of public health interventions. Important to immunoprevention beyond viral vaccines, genetic drivers of premalignant progression were associated with increasing immunosuppressive TME; and Kras vaccine efficacy in pancreas genetically engineered mouse (GEM) model required an inhibitory adjuvant (Treg depletion). In addition to developing new (e.g., epigenetic) TME regulators, recent mechanistic studies of repurposed drugs (aspirin, metformin, and tamoxifen) have identified potent immune activity. Just as precision medicine and immune-oncology are revolutionizing cancer therapy, these approaches are transforming cancer prevention. Here, we set out a brief agenda for the immediate future of cancer prevention research (including a “Pre-Cancer Genome Atlas” or “PCGA”), which will involve the inter-related fields of precision medicine and immunoprevention – pivotal elements of a broader domain of personalized public health. Cancer Prev Res; 9(1); 2–10. ©2016 AACR.